Microsoft's turnaround strategy seems to be working - the company beat analyst expectations on commercial cloud revenue in its first quarter earnings.
Several "safety" stocks have reversed their paths higher this year; and some still may be worth a buy.
FANG stocks are up more than 6 percent in October, compared to a 2 percent loss by an equal-weight basket of tech stocks
Energy, tech and financials should all help push earnings higher next year, Morgan Stanley's Andrew Slimmon says.
Donald Trump on Thursday accused Hillary Clinton of "inappropriately" receiving debate questions ahead of time.
These are the stocks posting the largest moves after the bell, including: Paypal, Microsoft, Alkermes and more.
Rich Pzena made his comments on Thursday in an interview with CNBC's Scott Wapner on "Halftime Report."
Paypal reported earnings Thursday after the bell, meeting Wall Street expectations of 35 cents per share.
Whether it’s celebrity investors or small businesses on Main Streets across America, these are the stories of the entrepreneurial heroes behind the movement
As a result of stolen email messages released by WikiLeaks, we now know what President Barack Obama's email address was during the presidential transition.
UBS says iPhone 7 interest in China is "tepid."
Senior executives from both companies have begun chats over business strategies, according to Bloomberg.
Poor Samsung. Even the leader of the free world won't spare them from ridicule, The Verge reports.
Apple says it has been buying Apple products labeled as genuine on Amazon and has found nearly 90 percent are counterfeit.
A fully autonomous Tesla trip from Los Angeles to New York by the end of 2017 may not be realistic, says a former NHTSA official.
Following the announcement of new hardware for Tesla Autopilot, one analyst identifies factors that could drive Tesla's stock up.
According to Whitepages data, There are 4,788 people in America who share the last name Trump — and they're sick of the election, Vox reports.
Critics who say there is a bubble in the Chinese economy are getting a lot wrong, two tech industry leaders said on Thursday.
Alkermes said its lead depression drug met the main goal of a late-stage trial, sending its shares up 48 percent in extended trading.